Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ CM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Dynavax Technologies Corp

+ Add to Watchlist

DVAX:US

20.5100 USD 0.3950 1.96%

As of 20:10:00 ET on 05/01/2015.

Snapshot for Dynavax Technologies Corp (DVAX)

Open: 19.9900 Day's Range: 19.9201 - 21.0300 Volume: 355,405
Previous Close: 20.1150 52wk Range: 12.5000 - 26.8900 1-Yr Rtn: +34.93%

Stock Chart for DVAX

No chart data available.
  • DVAX:US 20.5100
  • 1D
  • 1M
  • 1Y
20.1150
Interactive DVAX Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for DVAX

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -3.3500
Est. EPS (USD) (12/2015) -2.9060
Est. PEG Ratio -
Market Cap (M USD) 593.27
Shares Outstanding (M) 28.93
30 Day Average Volume 510,406
Price/Book (mrq) 5.3697
Price/Sale (ttm) 48.8737
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/05/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for DVAX

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for DVAX

Dynavax Technologies Corporation discovers, develops, and is seeking to commercialize products based on immunostimulatory sequences. The Company is developing products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using approaches that alter immune system responses in specific ways.

Eddie GrayChief Executive OfficerRobert Lee CoffmanSenior VP/Chief Scientific Ofcr
David NovackSenior VP:Ops & QualityMichael S OstrachVP/CFO/Chief Bus Ofcr/Gen Cnsl
More Company Profile & Key Executives for DVAX

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil